board of directors – Saudi Mirror http://www.saudimirror.com News On-line Mon, 25 Mar 2024 11:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.3.2 Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership http://www.saudimirror.com/?p=218472/ http://www.saudimirror.com/?p=218472/#respond Mon, 25 Mar 2024 11:00:00 +0000 http://www.saudimirror.com/?p=218472 TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 25, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd (Nasdaq: CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today announced the appointment of David Gee as Chief Marketing Officer (CMO). Mr. Gee brings more than 25 years of global sales and marketing expertise and will serve as a member of Cellebrite’s executive leadership team, reporting directly to CEO Yossi Carmil. He will oversee Cellebrite’s global marketing strategy and execution to help the Company capitalize on the major growth opportunities ahead in the digital investigations marketplace.

Mr. Gee joins Cellebrite as digital crimes escalate exponentially, and criminal activities become more sophisticated, requiring law enforcement and enterprises to apply more advanced tools to fully capture, manage and analyze all the digital evidence at their disposal. Cellebrite’s end–to–end Case–to–Closure (C2C) platform helps investigative teams in both public and private sectors reach time–to–evidence quicker and close cases faster, smarter and more defensibly than ever before.

“Cellebrite stands on the precipice of an unparalleled opportunity. As we forge ahead, scaling our extraordinary growth, we welcome aboard David Gee, a strategic marketing luminary,” said Yossi Carmil, Cellebrite CEO. “His seasoned expertise will propel our global expansion. David embodies our vision and champions the ethical and responsible use of technology, recognizing its power to safeguard our world. Together, we’ll redefine what’s possible.”

As a seasoned industry veteran, Mr. Gee brings a wealth of experience to his role as CMO. His previous roles have left indelible marks, and now he’s ready to propel Cellebrite to new heights. Most recently, he served as CMO at Coherent Inc. where he digitally transformed the business and was part of the management team that doubled the market capitalization within two years. Previously, David was CMO at Imperva, Zuora and Infoblox and held senior marketing and operational roles at Hewlett Packard, Yahoo!, Sun Microsystems and IBM.

“It is rare to find an opportunity that fits my personal values, while also aligning with my skill set. I am thrilled to join Cellebrite and become part of such an important, mission–based business,” said Mr. Gee. “Cellebrite’s achievements to date are inspiring, and the opportunities ahead to further accelerate justice are exciting. I look forward to working with my new colleagues as we focus on executing the programs, campaigns, and initiatives that will broaden market awareness and adoption of the Company’s innovative digital investigative solutions.”

To learn more about Cellebrite and its Case–to–Closure Platform, please visit www.cellebrite.com.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, the following: helping our team further expand our business around the world; and executing the programs, campaigns and initiatives that will broaden market awareness of the Company’s innovative digital investigative solutions, fortify and expand our customer relationships globally, increase our market leadership and achieve our business objectives. Such forward–looking statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on March 21, 2024 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media 

Victor Cooper 
Sr. Director of Corporate Communications + Content Operations 
Victor.cooper@cellebrite.com 
+1 404.804.5910 

Investor Relations 

Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd321307–8ce5–4237–86b7–324ddbd27380


GLOBENEWSWIRE (Distribution ID 9078473)

]]>
http://www.saudimirror.com/?p=218472/feed/ 0
Phosphorus تصدر قرارًا بتعيين Osama AlZoubi نائباً للرئيس الإقليمي للشركة في المملكة العربية السعودية والشرق الأوسط http://www.saudimirror.com/?p=218406/ Thu, 14 Mar 2024 01:40:44 +0000 http://www.saudimirror.com/?p=218406 ناشفيل، تينيسي, March 14, 2024 (GLOBE NEWSWIRE) — أعلنت اليوم شركة Phosphorus Cybersecurity Inc.‎، الرائدة في مجال الإدارة الموحدة للعمليات الأمنية القائمة على الأساليب الاستباقية لإنترنت الأشياء الممتد (xIoT)، عن تعيين Osama AlZoubi نائبًا للرئيس الإقليمي للشركة في المملكة العربية السعودية والشرق الأوسط. سوف يشرف AlZoubi خلال توليه مهام منصبه الجديد على نمو شركة Phosphorus وتطورها في المملكة العربية السعودية والشرق الأوسط، حيث تقوم الشركة بتوسيع تواجدها في المنطقة من خلال منصة حماية النظام السيبراني المادي (CPS) الأفضل في فئتها التي تستطيع الكشف عن النطاق الكامل لأجهزة إنترنت الأشياء، والتكنولوجيا التشغيلية، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية فضلاً عن معالجة هذا النطاق ومراقبته وإدارته.

تشهد منطقة المملكة العربية السعودية والشرق الأوسط تقدمًا تكنولوجيًا كبيرًا، لا سيما في مجالات الطاقة والتصنيع الذكي والتنمية الحضرية نظرًا لكونها واحدة من أسرع المناطق الاقتصادية نموًا في العالم. هذا وتقود المملكة العربية السعودية قاطرة تحول كبير في المنطقة وذلك من خلال رؤية المملكة 2030 – حيث يتم تنفيذ العديد من المشاريع الضخمة والعملاقة مثل نيوم، وحديقة الملك سلمان، والدرعية بالإضافة إلى المربعة، ومشروع البحر الأحمر، والقدية. وفي ضوء ذلك، يتطلب التطور والتكامل السريع للأنظمة السيبرانية المادية المتقدمة في المنطقة توفير قدرات أمنية تتسم بمزيد من القوة لحماية أجهزة إنترنت الأشياء والتكنولوجيا التشغيلية الحساسة من التعرض للتهديدات المتزايدة جراء الهجمات السيبرانية. وعلى هذا النحو، سوف يحظى AlZoubi بدور فاعل في قيادة جهود Phosphorus لمساعدة الشركات العامة والخاصة في المنطقة على حد سواء على تحقيق أعلى مستويات الأمن السيبراني الاستباقي لجميع مباني إنترنت الأشياء الممتد الخاصة بها، بما في ذلك الأصول الأكثر حساسية للمهام والأصول الهامة للحياة.

وفي هذا السياق صرح Chris Rouland، الرئيس التنفيذي لشركة Phosphorus قائلاً “يتسم Osama بالبراعة في مجال الكمبيوتر علاوة على أنه قد شغل في السابق منصب رئيس قسم التكنولوجيا لدى شركة Cisco في منطقة الشرق الأوسط وأفريقيا، فضلاً عن أنه قد ساعد في تصميم العديد من الشبكات التي نعمل على تأمينها. إن ما يتمتع به من قدر كبير من المعرفة فضلاً عن خبرته الواسعة ستجعل منه إضافة هائلة لشركتنا وفريق القيادة العليا لدينا”. “يحظى الأمن السيبراني بأهمية بالغة في المملكة العربية السعودية التي تشهد معدلات نمو سريعة وفي جميع أنحاء منطقة الشرق الأوسط، حيث تضخ المزيد من الدول استثمارات في التقنيات المتقدمة، مثل المدن الذكية. وفي ذات السياق، تتطلب هذه الأصول الهامة التي تتعلق بإنترنت الأشياء والتكنولوجيا التشغيلية مستوى جديدًا من الحماية لا تستطيع الحلول الأمنية التقليدية الوفاء به. وسيحظى Osama بدور هام في توسيع نطاق عمليات منصة إنترنت الأشياء الممتد الخاصة بنا عبر هذه المنطقة لضمان حصول عملائنا على أعلى مستوى من الحماية الاستباقية للأنظمة السيبرانية المادية.”

وعلى الجانب الآخر، صرح السيد AlZoubi قائلاً “تمثل شركة Phosphorus إحدى الشركات الرائدة التي تتسم بالابتكار في مجال العمليات الأمنية حيث تتمتع بإمكانات هائلة على الصعيدين المحلي والدولي. “كما أنها تتفرد بالقدرة على اكتشاف النطاق الكامل لأصول إنترنت الأشياء، والتكنولوجيا التشغيلية، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية التي دائمًا ما تكون عرضة للهجمات المستمرة فضلاً عن معالجة هذا النطاق ومراقبته وإدارته بشكل استباقي. وينطبق هذا الأمر على المملكة العربية السعودية ومنطقة الشرق الأوسط وأفريقيا بشكل خاص، حيث لا يؤدي تطور التكنولوجيا المتقدمة إلى إيجاد فرص اقتصادية هائلة فحسب، بل يصل الأمر إلى احتمالية التعرض للتعطل الناجم عن برامج الفدية والهجمات المادية السيبرانية. أشعر بحماسة بالغة بانضمامي إلى هذه الشركة التي تحظى بالابتكار وإنني لأتطلع إلى تسريع وتيرة نموها بالمنطقة.

يتسم AlZoubi بكونه أحد رواد التكنولوجيا والأعمال، ويتمتع بخبرات عريضة تربو على 25 عامًا في مجال تكنولوجيا المعلومات والاتصالات. ومن بين أبرز المجالات المحورية التي يبرع بها يأتي الأمن السيبراني والذكاء الاصطناعي وإنترنت الأشياء فضلاً عن مراكز البيانات والبرمجيات والبنية التحتية. وعلى مدى مسيرته المهنية، حظي AlZoubi بدور فاعل في العديد من مبادرات البحث والتطوير المتقدمة، بما في ذلك براءة اختراع لنظام إنترنت الأشياء اللاسلكي تحت الماء.

شغل AlZoubi العديد من المناصب القيادية على الصعيد الدولي قبل انضمامه إلى Phosphorus، حيث شغل مؤخرًا منصب رئيس قسم التكنولوجيا لدى شركة Cisco لمنطقة الشرق الأوسط وأفريقيا. كما تولى أيضًا قيادة فرق الهندسة وتصميم الأعمال، لدفع وتيرة التحول الرقمي عبر منطقة الشرق الأوسط وأفريقيا، مع قيادة مبادرات الرقمنة والابتكار ونمو الأعمال عبر القطاعين العام والخاص في المملكة العربية السعودية والشرق الأوسط وأفريقيا، وبالإضافة إلى ذلك فهو أيضًا مؤلف كتاب “The Digital Disruption”، وهو حاصل على براءة اختراع في مجال إنترنت الأشياء، كما أن له العديد من المنشورات في مجلة هارفارد بزنس ريفيو العربية. حصل AlZoubi على درجة بكالوريوس العلوم في هندسة الكمبيوتر من جامعة إلينوي في شيكاغو بالإضافة إلى ماجستير العلوم في علوم الكمبيوتر من معهد إلينوي للتكنولوجيا في شيكاغو.

تتسم منصة Phosphorus المعترف بها من جانب Gartner وهي منصة إدارة العمليات الأمنية الموحدة لإنترنت الأشياء الممتد بكونها منصة الحماية الوحيدة للنظام السيبراني المادي في القطاع حيث تغطي مجال الأمن والإدارة الكاملة لإنترنت الأشياء بشكل استباقي. ومن خلال قدرتها الفريدة على التواصل المباشر مع ما يزيد عن مليون طراز من الأجهزة (بما في ذلك أكثر من 600 مورد) بلغاتهم الأصلية، تمكن منصة Phosphorus جميع المؤسسات من اكتشاف أي أجهزة تتعلق بإنترنت الأشياء، والتكنولوجيا التشغيلية، وإنترنت الأشياء الطبية وتقويتها ومعالجتها وإدارتها على نحو آمن، بما في ذلك الأصول الأكثر حساسية للمهام والحياة.

للتعرف على المزيد من المعلومات حول شركة Phosphorus، يمكنكم زيارة الموقع الإلكتروني www.phosphorus.io أو متابعتنا في الفعاليات القادمة، مثل RSAC، وBlack Hat، وDEF CON.

نبذة حول PHOSPHORUS

Phosphorus Cybersecurity®‎ هي إحدى المنصات الرائدة في مجال حماية النظام السيبراني المادي حيث تقدم نهجًا استباقيًا لإدارة العملية الأمنية ومنع حدوث الاختراقات التي يتعرض لها إنترنت الأشياء، وتكنولوجيا التشغيل، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية. وقد تم تصميم هذه المنصة للتعرف على الأنظمة السيبرانية المادية سريعة النمو وغير المعروفة وغير الخاضعة للرقابة وتأمينها في نطاق إنترنت الأشياء الممتد، هذا وتوفر منصة إدارة العمليات الأمنية الموحدة الخاصة بإنترنت الأشياء الممتد إدارة أمنية لا مثيل لها فضلاً عن منع حدوث الاختراقات عبر جميع القطاعات – مما يجعلها توفر دقة عالية في الاكتشاف وتقييم المخاطر، والتقوية والمعالجة الاستباقية بالإضافة إلى المراقبة والإدارة المستمرة. ومن خلال الاكتشاف الذكي الفعال لإنترنت الأشياء الممتد وتقييم المخاطر الحاصل على براءة اختراع، تقوم Phosphorus بأتمتة عملية تخفيف ومعالجة أهم نقاط الضعف في الأجهزة الخاصة بإنترنت الأشياء، وتكنولوجيا التشغيل، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية – بما في ذلك مخزون الأصول غير المعروف وغير الدقيق، وبيانات الاعتماد الافتراضية فضلاً عن البرمجيات الثابتة القديمة والضعيفة، والتكوينات التي تتسم بالخطورة، والأجهزة المحظورة ومنتهية الصلاحية بالإضافة إلى الشهادات منتهية الصلاحية أو الموقعة ذاتيًا. يمكنكم متابعة Phosphorus عبر LinkedIn، Twitter، Threads، بالإضافة إلى YouTube، كما يمكن التعرف على المزيد من المعلومات عبر الموقع الإلكتروني www.phosphorus.io 

مسؤول الاتصالات الإعلامية:


GLOBENEWSWIRE (Distribution ID 9063443)

]]>
Phosphorus Appoints Osama AlZoubi as Regional Vice President of Saudi Arabia and Middle East http://www.saudimirror.com/?p=218405/ Wed, 13 Mar 2024 12:07:00 +0000 http://www.saudimirror.com/?p=218405 NASHVILLE, Tenn., March 13, 2024 (GLOBE NEWSWIRE) — Phosphorus Cybersecurity Inc., the leading provider of unified, prevention–based security management for the xTended Internet of Things (xIoT), today announced the appointment of Osama AlZoubi as the Regional Vice President, Saudi Arabia and the Middle East. In his new role, AlZoubi will oversee Phosphorus’ growth and development throughout the Kingdom of Saudi Arabia and the Middle East, as the company expands its presence in the region with its best–of–breed Cyber–Physical System (CPS) Protection Platform that discovers, remediates, monitors, and manages the full scope of IoT, OT, IIoT, and IoMT devices.

As one of the world’s fastest growing economic regions, Saudi Arabia and the Middle East are experiencing significant technological progress, particularly in energy, smart manufacturing, and urban development. Saudi Arabia is also spearheading a monumental transformation in the region with its Vision 2030 – with mega and giga projects like NEOM, King Salman Park, Diriyah, Murabba, the Red Sea Project, and Qiddiya. The region’s rapid development and integration of advanced Cyber–Physical Systems requires more robust security capabilities to protect sensitive IoT and OT devices from the growing threat of cyber attacks. AlZoubi will play a critical role in leading Phosphorus’ efforts to assist the region’s public and private enterprises in achieving the highest level of proactive cybersecurity for their entire xIoT estates, including the most sensitive mission–critical and life–critical assets.

“Osama is an accomplished computer scientist and former CTO of Cisco Middle East and Africa who helped build many of the networks we work to secure. His knowledge and experience will make him a tremendous asset to our organization and senior leadership team,” said Chris Rouland, CEO of Phosphorus. “Cybersecurity is critically important in fast–developing Saudi Arabia, and across the Middle East region, as more countries invest in advanced technologies, such as smart cities. These critical IoT and OT assets require a new level of protection that traditional security solutions simply cannot provide. Osama will play a crucial role in expanding our xIoT platform across this region to ensure our customers have the highest level of proactive protection for their Cyber–Physical Systems.”

“Phosphorus is a groundbreaking and disruptive security company with remarkable potential in the region and throughout the world,” said AlZoubi. “Only Phosphorus has the capability to proactively discover, remediate, monitor, and manage the full range of IoT, OT, IIoT, and IoMT assets that represent an ever–expanding attack surface. This is especially true in the Kingdom of Saudi Arabia, and throughout the Middle East and Africa, where high–tech development is not only creating massive economic opportunity, but also the potential for disruption from ransomware and cyber–physical attacks. I am excited to join this innovative company and I look forward to accelerating its growth in the region.”

AlZoubi is a seasoned technology and business leader with over 25 years of extensive experience in information and communications technology (ICT). His expertise encompasses pivotal domains such as cybersecurity, artificial intelligence (AI), IoT, data centers (DC), software (SW), and infrastructure. Throughout his career, he has actively engaged in cutting–edge research and development initiatives, including a patent for a wireless underwater IoT system.

Prior to joining Phosphorus, AlZoubi held multiple global leadership roles and most recently served as Chief Technology Officer (CTO) for Cisco in the Middle East and Africa. AlZoubi led the Engineering and Business Architecture teams, to drive Digital Transformation across the MEA region, while driving the digitization initiatives, innovation, and business growth across the private and public sector in Saudi Arabia, the Middle East, and Africa. AlZoubi is also the author of “The Digital Disruption”, he holds a patent in the IoT field, and he has multiple publications in Harvard Business Review Arabia. He has a Bachelor of Science degree in Computer Engineering from the University of Illinois at Chicago (UIC), and a Master of Science in Computer Science from the Illinois Institute of Technology (IIT) in Chicago.

Phosphorus’ Gartner–recognized Unified xIoT Security Management Platform is the industry’s only CPS Protection Platform proactively covering the entire security and management lifecycle for xIoT. Through its unique ability to directly communicate with over one million device models (including over 600 vendors) in their native languages, Phosphorus’ platform empowers all organizations to safely discover, harden, remediate, and manage any IoT/OT/IoMT device, including the most sensitive mission–critical and life–critical assets.

For more information about Phosphorus, visit www.phosphorus.io, or see us at upcoming conferences, such as RSAC, Black Hat, and DEF CON.

ABOUT PHOSPHORUS

Phosphorus Cybersecurity® is the leading CPS Protection Platform delivering a proactive approach to security management and breach prevention for the exploding IoT, OT, IIoT, and IoMT attack surface. Designed to find and secure the rapidly growing, unknown, and often unmonitored world of Cyber–Physical Systems across the xTended Internet of Things landscape, our Unified xIoT Security Management Platform provides unmatched security management and breach prevention across every industry vertical—delivering high–fidelity discovery and risk assessment, proactive hardening and remediation, and continuous monitoring and management. With patented xIoT Intelligent Active Discovery and risk assessment, Phosphorus automates the mitigation and remediation of the most significant IoT, OT, IIoT, and IoMT device vulnerabilities – including unknown and inaccurate asset inventory, default credentials, out–of–date and vulnerable firmware, risky configurations, banned and end–of–life devices, and expired or self–signed certificates. Follow Phosphorus on LinkedIn, Twitter, Threads, and YouTube, and learn more at www.phosphorus.io 


GLOBENEWSWIRE (Distribution ID 9062687)

]]>
Dentsu Appoints Shirli Zelcer to Chief Data and Technology Officer http://www.saudimirror.com/?p=218374/ Thu, 07 Mar 2024 09:30:00 +0000 http://www.saudimirror.com/?p=218374 TOKYO, March 07, 2024 (GLOBE NEWSWIRE) — Dentsu (brand: dentsu; Head Office: Dentsu Group Inc.; Location: Tokyo; Representative: President and Global CEO Hiroshi Igarashi) today announced the appointment of Shirli Zelcer as Chief Data and Technology Officer (CDTO), sitting on dentsu’s Group Management Team. In this role, Zelcer will be responsible for all of dentsu’s client–facing data–driven, analytics and technology–enabled products and platforms, driving innovation and sustainable growth for clients.

Dentsu also announced today that Steve Simpson has been appointed as President, Data, Audiences and Technology, dentsu and Shiva Vannavada as President, Data and Technology Solutions, dentsu. Simpson will join the Global Media Practice leadership team to support the development of a winning Media Practice community that delivers continued excellence in its offering to clients, driving client growth and transformation. In his newly created role, Simpson will be responsible for the strategic planning and delivery of a globally–scaled, data–driven and technology–enabled audience platform that drives growth for clients, while Vannavada will focus on creating synergies across product and platforms, AI innovation, analytics and across Dentsu Global Services (DGS).  

Zelcer brings over 20 years of experience in analytics and insights, business advisory and organizational design, AI and data science, and cloud and marketing technologies. She was most recently the Global Head of Analytics and Technology at Merkle, where she led a global division of over 5,600 practitioners across the Americas, EMEA, and APAC. In her new role at dentsu, Zelcer will be responsible to innovate the vision, roadmap, development and commercial impact of dentsu's data and tech strategy across our three core practice areas: Media, CXM and Creative, working closer with Practice leads and Jean Lin, Global President – Global Practices, dentsu. The role will lead a newly formed team brought together from these Practice areas to drive consistency, interoperability and ultimately to deliver growth to dentsu’s clients through more unified capabilities. 

Joining from Publicis, in his new role, Simpson will lead a global team of experts from across data management, identity, personalization, media activation and dynamic creative production, and partner with dentsu’s global products and platforms team to integrate and scale the platform across dentsu’s Global Practices.

Simpson will also be accountable for evolving dentsu’s global media delivery platform. Enabled by programmatic media delivery, enriched with 1st, 2nd and 3rd party data, it will leverage dentsu’s leading Merkury products suite to drive client competitiveness. 

Having previously served as Global Chief Product and Technology Officer, dentsu Solutions, Vannavada’s expanded responsibilities as President, Data and Technology Solutions will include driving cross–practice and product collaboration, nurturing dentsu’s AI Connective community and leading his team to contribute to tech–enabled solutions and strategy. 

“Innovation across data and technology are two of dentsu’s most critical points of differentiation, having led the market for many years in the development, adoption and application of proprietary platforms which give our clients the edge,” said Hiroshi Igarashi, President and Global CEO, dentsu. “We are very proud to appoint Shirli, Steve and Shiva into these new strategic roles which bring together our efforts across the organization, honing our capabilities and ensuring that dentsu and our clients remain at the forefront of innovation.”

The leadership of the broader Data and Tech organization at dentsu includes: Head of Product, Matt Seeley, and Sunil Rao leading Analytics, and Peter Rogers leading Data Platforms. DGS will also now report into Zelcer’s Data and Technology structure and in turn, Zelcer will report into Michael Komasinski, CEO, dentsu Americas & Global President – Data & Technology, dentsu. 

Quotes: 

“During her time at Merkle, Shirli brought together teams from around the world to collaborate on vital programs, ranging from data infrastructure implementation to advanced media mix modeling, personalization strategies and the development of bespoke AI solutions,” commented Michael Komasinski, CEO, dentsu Americas & Global President – Data & Technology, dentsu. “With her vast experience of successfully partnering with clients, alongside a proven ability to solve business challenges with cutting–edge technology solutions, I'm truly excited to see the impact that Shirli will have in her new expanded global role at dentsu.” 

“It is a very exciting prospect to move into this new role at a time when not only is dentsu at a pivotal moment in its history, but data and technology have never evolved at a faster pace,” remarked Shirli Zelcer, Chief Data and Technology Officer, dentsu. “As a group, we have already made some big moves into AI over the last few years, but I truly see the combination of AI with dentsu proprietary and partner technologies as a major differentiator for our clients. I’m looking forward to broadening the impact I can have across dentsu and working closely with the talented leaders and teams across our tech community.”

Steve Simpson, President, Data, Audiences and Technology, dentsu, said: “I am thrilled to join dentsu at this exciting time of transformation and innovation. Data and technology are at the heart of the media industry and the integrated opportunity across Practices at dentsu in vast. I look forward to working with the talented teams throughout dentsu to build a world–class platform that will deliver value and innovation for our clients, helping them achieve their business goals.” 

Shiva Vannavada, President, Data and Technology Solutions, dentsu, commented: “Since I began my journey at dentsu, we have been actively planning our future with AI and I am excited to take on this new expanded remit as we enter into what will undoubtedly be a transformational year for AI and the products and solutions we build using it. At dentsu, we don’t consider AI as a standalone technology, it is part of the fabric of our data, technology and product capabilities, ingrained into every practice and present in every agency brand. This makes us naturally more collaborative, more integrated and faster to market for our clients, and I look forward to working with teams across dentsu to break new ground in what is possible across data and tech for our clients.” 

About dentsu  

Dentsu is the network designed for what’s next, helping clients predict and plan for disruptive future opportunities and create new paths to growth in the sustainable economy. Taking a people–centered approach to business transformation, we use insights to connect brand, content, commerce and experience, underpinned by modern creativity. As part of Dentsu Group Inc. (Tokyo: 4324; ISIN: JP3551520004), we are headquartered in Tokyo, Japan, and our 71,000–strong employee base of dedicated professionals work across four regions (Japan, Americas, EMEA and APAC). Dentsu combines Japanese innovation with a diverse, global perspective to drive client growth and to shape society.

https://www.dentsu.com/  
https://www.group.dentsu.com/en/ 

Contact:

Matt Cross
Phone: +442074306319
Email: matt.cross@dentsu.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf533a57–ac1f–4ad2–87e5–340b90ec6957


GLOBENEWSWIRE (Distribution ID 1000927842)

]]>
Zenas BioPharma beruft Patricia Allen in den Verwaltungsrat http://www.saudimirror.com/?p=218373/ Wed, 06 Mar 2024 23:59:07 +0000 http://www.saudimirror.com/?p=218373 WALTHAM, Massachusetts, March 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, ein weltweit tätiges Biopharmazieunternehmen, dessen Ziel eine führende Rolle in der Entwicklung und Kommerzialisierung von Entzündungs– und Immunologietherapien ist, gab heute die Ernennung von Patricia Allen in den Verwaltungsrat des Unternehmens bekannt, in dem sie auch als Vorsitzende des Prüfungsausschusses fungieren wird. Frau Allen wird sich mit mehr als 20 Jahren Erfahrung in den Bereichen Finanzen, Anlegerbeziehungen, Geschäftsentwicklung, Personalwesen, Betrieb und IT in globalen börsennotierten und privaten Biotechnologieunternehmen in den Verwaltungsrat von Zenas einbringen.

„Wir freuen uns, Frau Allen in unserem Verwaltungsrat begrüßen zu dürfen“, so Lonnie Moulder, Gründer und Verwaltungsratsvorsitzender von Zenas BioPharma. „Sie hat erfolgreich organisationsübergreifende Funktionen geleitet und war im Verwaltungsrat von privaten und börsennotierten globalen Biotechnologieunternehmen tätig. Wir freuen uns auf Frau Allens Beitrag zur nächsten Wachstumsphase von Zenas, während wir unsere Mission vorantreiben, transformative immunologische Therapien für Patienten zu entwickeln und zu vermarkten, die diese dringend benötigen.“

„Ich freue mich auf die Zusammenarbeit mit dem erfahrenen Team von Zenas und dem Verwaltungsrat, die durch disziplinierte Umsetzung der Pipeline und Geschäftsentwicklung ein führendes, auf Entzündungen und Immunologie fokussiertes globales Biopharmazieunternehmen aufbauen“, so Frau Allen. „Dies ist eine aufregende Zeit für Zenas, da das Unternehmen aktuell versucht, mehrere Programme in der Klinik voranzutreiben, um letztendlich das Leben von Menschen mit Autoimmunkrankheiten zu verbessern.“

Frau Allen war zuletzt als Chief Financial Officer bei Vividion Therapeutics tätig, wo sie kürzlich ausschied. Während ihrer Zeit bei Vividion leitete sie das Fundraising und die Übernahme des Unternehmens durch die Bayer AG mit, während das Unternehmen wuchs und mehrere Programme in Richtung Klinik vorantrieb. Derzeit ist sie Mitglied des Verwaltungsrats und Vorsitzende des Prüfungsausschusses von Deciphera Pharmaceuticals, SwanBio Therapeutics und Anokion. Darüber hinaus war sie in der Vergangenheit Mitglied des Verwaltungsrats und Vorsitzende des Prüfungsausschusses von Inversago Pharma und Yumanity Therapeutics.

Vor ihrer Tätigkeit bei Vividion hielt Frau Allen die Position des Chief Financial Officer bei Zafgen, Inc. (jetzt Larimer Therapeutics) inne. Zuvor war sie Vice President of Finance and Treasurer, Principal Financial Officer bei Alnylam Pharmaceuticals, Inc. sowie Director of Finance bei Alkermes, Inc. und Wirtschaftsprüferin bei Deloitte & Touche, LLP. Sie besitzt einen B.S.–Abschluss in Betriebswirtschaft vom Bryant College.

Über Zenas BioPharma

Zenas BioPharma ist ein weltweit tätiges Biopharmazieunternehmen, das sich zum Ziel gesetzt hat, ein führendes Unternehmen in der Entwicklung und Vermarktung von entzündungs– und immunologieorientierten Therapien für dringend darauf angewiesene Patienten in aller Welt zu werden. Zenas verfügt über klinische Entwicklungskapazitäten und ist weltweit tätig, um ein Portfolio potenziell differenzierter Autoimmuntherapeutika in Bereichen mit hohem medizinischen Bedarf zu entwickeln. Wir nutzen die Erfahrung und die Fähigkeiten unseres Führungsteams und unsere etablierten Netzwerke in der Biopharmaziebranche, um Therapien zu entwickeln, die das Leben von Menschen mit Autoimmunerkrankungen und seltenen Krankheiten verbessern können. Für weitere Informationen über Zenas BioPharma besuchen Sie bitte www.zenasbio.com und folgen Sie uns auf X (früher Twitter) unter @ZenasBioPharma sowie LinkedIn.

Anleger– und Medienkontakt:
Argot Partners
Zenas@argotpartners.com


GLOBENEWSWIRE (Distribution ID 9059519)

]]>
Zenas BioPharma Nomeia Patricia Allen para o Conselho Diretor http://www.saudimirror.com/?p=218372/ Wed, 06 Mar 2024 23:59:07 +0000 http://www.saudimirror.com/?p=218372 WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias voltadas para inflamações e imunologia, divulgou hoje a nomeação de Patricia Allen para o Conselho Diretor, onde atuará também como Presidente do Comitê de Auditoria. A Sra. Allen ingressa no Conselho Diretor da Zenas com mais de 20 anos de experiência liderando finanças, relações com investidores, desenvolvimento de negócios, recursos humanos, operações e TI em empresas globais públicas e privadas de biotecnologia.

“Estamos muito contentes com a vinda de Patty para o nosso Conselho Diretor”, disse Lonnie Moulder, Fundador e Diretor Executivo da Zenas BioPharma. “Ela liderou com sucesso funções interorganizacionais e atuou no conselho diretor de empresas privadas e públicas de biotecnologia global. Estamos prontos para as contribuições de Patty para a próxima fase do crescimento da Zenas, à medida que avançamos na nossa missão de desenvolver e comercializar terapias transformadoras baseadas em imunologia para pacientes necessitados.”

“Estou pronta para colaborar com a experiente equipe da Zenas e o Conselho Diretor, que estão ampliando uma empresa biofarmacêutica global líder em inflamação e imunologia por meio da execução disciplinada de pipeline e desenvolvimento de negócios”, disse a Sra. Allen. “A Zenas está muito empolgada com o progresso dos seus múltiplos programas clínicos que irão aprimorar as vidas das pessoas que sofrem de doenças autoimunes.”

Recentemente, a Sra. Allen atuou como Diretora Financeira da Vividion Therapeutics, de onde se aposentou recentemente. Na Vividion, ela co liderou a captação de recursos e a aquisição da empresa pela Bayer AG, durante o crescimento e avanço da empresa com vários programas em direção à clínica. Ela atua no conselho diretor e como presidente do comitê de auditoria da Deciphera Pharmaceuticals, SwanBio Therapeutics e Anokion, além de ser ex–membro do conselho e presidente do comitê de auditoria da Inversago Pharma e Yumanity Therapeutics.

Antes de ingressar na Zenas, a Sra. Allen atuou como Diretora Financeira da Zafgen, Inc. (atual Larimer Therapeutics). Anteriormente, ela foi Vice–Presidente de Finanças e Tesoureira, Diretora Financeira Principal da Alnylam Pharmaceuticals, Inc.; Diretora de Finanças da Alkermes, Inc.; e Auditora da Deloitte & Touche, LLP. Ela é formada em Administração de Empresas pelo Bryant College.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias voltadas para inflamações e imunologia para pacientes necessitados em todo o mundo. Com desenvolvimento clínico e operações globais, a Zenas está avançando um portfólio de terapêuticas autoimunes potencialmente diferenciadas em áreas de alta necessidade médica. Aproveitamos a experiência e a capacidade da nossa equipe de gestão executiva a das nossas existentes na indústria biofarmacêutica em busca do desenvolvimento de terapias que possam melhorar as vidas das pessoas com doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga–nos no (ex Twitter ) em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Argot Partners
Zenas@argotpartners.com


GLOBENEWSWIRE (Distribution ID 9059519)

]]>
Patricia Allen rejoint le Conseil d’administration de Zenas BioPharma http://www.saudimirror.com/?p=218370/ Wed, 06 Mar 2024 23:59:07 +0000 http://www.saudimirror.com/?p=218370 WALTHAM, Massachusetts, 07 mars 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la commercialisation de thérapies orientées sur l’inflammation et l’immunologie, annonce la nomination de Patricia Allen à son Conseil d’administration et à la Présidence de son comité d’audit. Mme Allen rejoint le Conseil d’administration de Zenas après avoir dirigé pendant plus de 20 ans différentes divisions pour le compte de sociétés biotechnologiques internationales publiques et privées, notamment les départements des finances, relations avec les investisseurs, développement commercial, ressources humaines, opérations et informatique.

À propos de cette nomination, Lonnie Moulder, fondateur et PDG de Zenas BioPharma a déclaré : « Nous sommes ravis d’accueillir Patty au sein de notre Conseil d’administration. Elle a piloté avec succès des divisions transverses pour différentes entreprises, et a siégé au Conseil d’administration de sociétés biotechnologiques d’envergure mondiale des secteurs public et privé. Nous attendons avec impatience sa participation à la prochaine phase de croissance de Zenas, à l’heure où notre mission visant à développer et distribuer des immunothérapies modératrices du changement pour les patients qui en ont besoin prend de l’ampleur. ».

« J’ai hâte de travailler avec le concours des équipes expérimentées de Zenas et son Conseil d’administration, qui bâtissent ensemble une société biopharmaceutique internationale de premier plan axée sur des stratégies thérapeutiques orientées sur l’inflammation et l’immunologie au prix d’une exécution rigoureuse de leur pipeline et du développement commercial » observe Mme Allen, avant de poursuivre : « Le laboratoire Zenas traverse une période exaltante à l’heure où il s’efforce d’atteindre la phase clinique pour plusieurs de ses programmes dans l’objectif d’améliorer la vie des patients atteints de maladies auto–immunes ».

Actuellement retraitée, Mme Allen occupait encore très récemment la Direction des affaires financières de Vividion Therapeutics, dont elle a codirigé la levée de fonds et l’acquisition de Bayer AG, au moment où la société était en pleine croissance et faisait progresser plusieurs de ses programmes vers la phase clinique. Elle figure actuellement parmi les membres du Conseil d’administration de Deciphera Pharmaceuticals, SwanBio Therapeutics et Anokion, dont elle préside les comités d’audit, après avoir siégé aux Conseils d’administration des sociétés Inversago Pharma et Yumanity Therapeutics et en avoir également présidé les comités d’audit.

Avant son passage chez Vividion, Mme Allen pilotait la Direction financière de Zafgen, Inc., aujourd’hui Larimer Therapeutics. Avant cela, elle était vice–présidente des affaires financières, ainsi que trésorière et responsable financière principale chez Alnylam Pharmaceuticals, Inc., directrice des finances chez Alkermes, Inc., et auditrice chez Deloitte & Touche, LLP. Elle est titulaire d’une licence en gestion d’entreprises sanctionné par l’université privée américaine Bryant.

À propos de Zenas BioPharma

Zenas BioPharma est un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la commercialisation de thérapies orientées sur l’inflammation et l’immunologie pour répondre aux besoins des patients concernés partout dans le monde. À l’appui de ses capacités de développement et de ses installations de recherche clinique implantées aux quatre coins de la planète, Zenas fait progresser un ensemble de thérapies potentiellement différenciatrices ciblées sur les maladies auto–immunes dans des domaines thérapeutiques où les besoins médicaux restent insatisfaits. Son équipe de direction chevronnée et son réseau de partenaires commerciaux stimulent l’excellence opérationnelle visant à concevoir des traitements potentiellement révolutionnaires aux fins d’améliorer la qualité de vie des patients atteints de maladies auto–immunes rares. Pour en savoir plus sur Zenas BioPharma, rendez–vous sur www.zenasbio.com et suivez–nous sur X (anciennement Twitter) @ZenasBioPharma et LinkedIn.

Relations auprès des investisseurs et des médias :
Agence Argot Partners
Zenas@argotpartners.com


GLOBENEWSWIRE (Distribution ID 9059519)

]]>
Zenas BioPharma Appoints Patricia Allen to its Board of Directors http://www.saudimirror.com/?p=218356/ Wed, 06 Mar 2024 13:00:00 +0000 http://www.saudimirror.com/?p=218356 WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology–directed therapies, today announced the appointment of Patricia Allen to its Board of Directors, on which she also will serve as Chairperson of the Audit Committee. Ms. Allen joins the Zenas Board of Directors with over 20 years of experience leading finance, investor relations, business development, human resources, operations and IT at global public and private biotechnology companies.

“We are pleased to welcome Patty to our Board of Directors,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “She has successfully led cross–organizational functions and served on the board of directors of both private and public global biotechnology companies. We look forward to Patty’s contributions to the next phase of Zenas’ growth as we advance our mission to develop and commercialize transformative immunology–based therapies for patients in need.”

“I look forward to collaborating with the experienced Zenas team and Board of Directors, who are building a leading of inflammation and immunology–focused global biopharmaceutical company through disciplined pipeline execution and business development,” said Ms. Allen. “This is an exciting time for Zenas as they seek to progress multiple programs through the clinic to ultimately improve the lives of those living with autoimmune diseases.”

Ms. Allen most recently served as the Chief Financial Officer at Vividion Therapeutics, from where she recently retired. While at Vividion, she co–led led fundraising and the company’s acquisition by Bayer AG, as the company grew and advanced multiple programs towards the clinic. She currently serves on the board of directors and as chair of the audit committee of Deciphera Pharmaceuticals, SwanBio Therapeutics and Anokion, in addition to holding past board member and audit committee chair roles at Inversago Pharma and Yumanity Therapeutics.

Prior to Vividion, Ms. Allen was the Chief Financial Officer at Zafgen, Inc. (now Larimer Therapeutics). Earlier, she was Vice President of Finance and Treasurer, Principal Financial Officer of Alnylam Pharmaceuticals, Inc.; Director of Finance at Alkermes, Inc.; and Auditor at Deloitte & Touche, LLP. She received a B.S. in Business Administration from Bryant College.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology–directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. We leverage the experience and capabilities of our executive management team and our established networks throughout the biopharmaceutical industry as we seek to develop therapies that can improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X (formerly Twitter) at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com


GLOBENEWSWIRE (Distribution ID 9058707)

]]>
Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase http://www.saudimirror.com/?p=218355/ Wed, 06 Mar 2024 12:00:00 +0000 http://www.saudimirror.com/?p=218355 TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 06, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a leader in premier Digital Investigative solutions for the public and private sectors, today announced that Haim Shani has retired as a director of the Company, effective immediately. Mr. Shani had been a distinguished member of the Board since 2019, including two years as Chairman from August 2021 until August 2023.

Reflecting on his departure, Mr. Shani remarked, “The pace of progress at Cellebrite over the past year has been exceptional. As Cellebrite moves into its next phase of growth and market leadership, I believe it is the right moment for me to conclude my board service. I am leaving with pride in the Company’s accomplishments and confidence that the Company is well positioned to enjoy further success.”

Yossi Carmil, CEO of Cellebrite, expressed his gratitude for Mr. Shani’s contributions: “Haim has been an integral part of our journey, providing strategic guidance that has been vital to our achievements. On behalf of the board and the entire Cellebrite team, I want to thank him for his dedication and impactful contributions. We wish him the very best going forward.”

Following Mr. Shani’s departure, Cellebrite’s Board of Directors shall consist of nine directors.

Cellebrite moves forward as a global leader in Digital Investigative solutions, dedicated to enabling its customers to master the complexities of legally sanctioned digital investigations. The board and leadership team remain focused on addressing the evolving needs of its expansive global customer base through ongoing innovation and go–to–market initiatives and expanding its business around the world.

About Cellebrite

Cellebrite’s mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations to master the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze, and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, confidence that Company is well positioned to enjoy further success. Such forward–looking statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on April 27, 2023 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Contacts:

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com   
+1 404 804 5910


GLOBENEWSWIRE (Distribution ID 9058952)

]]>
Bitdeer Announces Appointment of Jihan Wu as New Chief Executive Officer as Linghui Kong Transitions to Chief Business Officer http://www.saudimirror.com/?p=218083/ Mon, 29 Jan 2024 13:30:00 +0000 http://www.saudimirror.com/?p=218083 SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world–leading technology company for blockchain and high–performance computing, today announced the appointment of Mr. Jihan Wu, the Company’s Founder and Chairman of its Board of Directors (the “Board”), as Chief Executive Officer of the Company, effective on March 1, 2024. In addition to his new role as Chief Executive Officer, Mr. Jihan Wu will remain as Chairman of the Company’s Board. The Company’s current Chief Executive Officer Mr. Linghui Kong will transition to the role of Chief Business Officer and will continue to serve as a member of the Company’s Board, also effective on March 1, 2024.

Jihan Wu, Founder and Chairman of Bitdeer, commented, “I’d like to thank Linghui for his valuable contributions to Bitdeer over the past three years. During his tenure, we have made significant progress in developing our business, strengthening our foundations, and positioning Bitdeer for its next growth phase. Linghui's transition to Chief Business Officer and my appointment as Chief Executive Officer enable both of us to focus on our respective areas of expertise. Furthermore, our realigned roles will empower us to make even greater contributions to Bitdeer’s long–term development and position us to fully capitalize on emerging strategic growth opportunities.”

“I am proud of the success Bitdeer has achieved thus far, and I am excited to lead our team through a new era of strategic development,” Mr. Wu continued. “Going forward, we will allocate our resources to develop cutting–edge technologies, cultivate a strong leadership team, attract more high–caliber individuals to join our ranks, and further bolster our corporate culture. Through these efforts and our ongoing commitment to excellence, I am confident Bitdeer will develop into a preeminent technology enterprise.”

Linghui Kong, the current Chief Executive Officer of Bitdeer, added, “Serving as Bitdeer’s CEO has been an extraordinary journey, filled with numerous accomplishments and invaluable experiences. It has been a privilege to lead such a dedicated team and advance our shared vision. I look forward to transitioning to my new role and working alongside Jihan to deliver sustainable value for our shareholders.”

About Bitdeer Technologies Group

Bitdeer is a world–leading technology company for blockchain and high–performance computing. Bitdeer is committed to providing comprehensive computing solutions for its customers. The Company handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The Company also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed datacenters in the United States, Norway, and Bhutan. To learn more, visit https://ir.bitdeer.com/.

Forward–Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward–looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward–looking statements, although not all forward–looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward–looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Bitdeer’s annual report on Form 20–F, as well as discussions of potential risks, uncertainties, and other important factors in Bitdeer’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward–looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward–looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Media Inquiries:
pr@bitdeer.com

Contacts

Investor Relations
Robin Yang, Partner
ICR, LLC
Email: Bitdeer.ir@icrinc.com
Phone: +1 (212) 537–5825

Public Relations
Brad Burgess, SVP
ICR, LLC
Email: Bitdeer.pr@icrinc.com
Phone: +1 (212) 537–4056

 


GLOBENEWSWIRE (Distribution ID 9027233)

]]>